Can polymorphisms predict response to antiarrhythmic drugs in atrial fibrillation?

Ready or not, routine use of genetic information is imminent in everyday cardiology practice. This impending reality stems partly from the declining cost of whole-genome sequencing that is now approaching the $1,000 barrier. Clinicians undoubtedly could use such insight in managing atrial fibrillation (AF), an extremely common and costly condition. However, analyzing and applying the vast amount of data housed in the human genome will clearly present huge challenges. With this backdrop, Parvez et al. (1) report in this issue of the Journal that response to certain ntiarrhythmic drugs (AADs) may be genotype dependent.